Panoramica dell'azienda
Guardian Pharmacy Services, Inc. operates as a pharmacy service company dedicated to providing a suite of technology-enabled services designed to assist residents of long-term health care facilities across the United States. The firm's individualized clinical, drug dispensing, and administration capabilities are specifically utilized to serve the unique needs within the healthcare infrastructure. This entity functions within the broader Healthcare sector, specifically classified under the Medical Care Facilities industry, positioning it as a specialized provider in the long-term care landscape. The company demonstrates significant scale with a market capitalization of $2.62 billion and annual revenue reaching $1.45 billion, supported by an operational workforce of 3,600 employees. These valuation and revenue figures indicate that Guardian Pharmacy Services holds a substantial market presence, suggesting its operations are integral to the functioning of the U.S. long-term health care system.
Salute finanziaria
The company reports trailing twelve-month revenue of $1.45 billion, with corresponding net income of $49.22 million and EBITDA standing at $102.62 million. The substantial gap between the $1.45 billion in revenue and the $49.22 million in net income reveals a cost structure where operational expenses, including cost of goods sold and operating overhead, consume approximately 96.6% of total revenue before interest and taxes. Free cash flow for the period was $73.88 million, which indicates a strong capacity to generate liquidity for capital expenditures, debt repayment, or strategic acquisitions without relying on external financing. Gross margin stands at 20.2%, reflecting the company's ability to price its pharmacy services above the direct cost of dispensing medications. Operating margin is recorded at 8.9%, highlighting the efficiency of internal management in controlling overhead costs relative to revenue generation. Profit margin sits at 3.4%, indicating the final bottom-line percentage retained after all expenses, taxes, interest, and other costs are deducted. The balance sheet shows $65.62 million in cash against $44.72 million in debt, resulting in a debt-to-equity ratio of 20.52, which suggests a leveraged balance sheet structure where equity funding is the primary source of capital. The current ratio of 1.38 indicates that the company holds sufficient current assets to cover its short-term liabilities with a 38% buffer, pointing to adequate short-term liquidity management. Return on Equity is calculated at 26.6%, while Return on Assets stands at 13.7%, metrics that collectively reveal how effectively management utilizes shareholder equity and total assets to generate profits.
Valutazione del valore
The trailing twelve-month P/E ratio is 52.12, while the forward P/E ratio is projected at 30.02. The significant difference between these two metrics implies that the market expects earnings to grow substantially in the coming years, as investors are pricing in a future where the current high valuation will compress toward the lower forward multiple. The price-to-book ratio is 12.51, which indicates a substantial market premium over the company's book value, suggesting that the market values the company's intangible assets, such as its technology-enabled service suite, far above its net tangible assets. The price-to-sales ratio stands at 1.81, and the EV/EBITDA multiple is 25.00; these alternative valuation metrics suggest that the company is valued based on revenue generation and earnings power that are significantly higher than the average for traditional utility or infrastructure plays, reflecting its growth characteristics. The 52-week high is $40.73 and the 52-week low is $19.17. Assuming the current market price is near the mid-to-upper range of this historical volatility, the stock trades at a level that captures the upside potential from the $19.17 low but remains below the peak of $40.73, reflecting the recent price action within the established trading range. The beta value is listed as N/A, which means there is no available data to quantify the stock's price volatility relative to the broader market index in the provided facts.
Growth & Income
Revenue growth over the last year is reported at 17.4%, whereas earnings growth is listed as N/A. The absence of reported earnings growth data prevents a direct comparison of whether earnings are expanding faster or slower than revenue, but the robust 17.4% revenue increase indicates a strong top-line expansion trajectory in the pharmacy services market. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This financial policy implies that the company chooses to reinvest all of its net income and free cash flow back into the business to fund growth initiatives, such as expanding its technology-enabled services to more long-term health care facilities, rather than distributing cash to shareholders. The overall growth and income profile is characterized by significant revenue expansion supported by a disciplined capital allocation strategy that prioritizes internal investment over shareholder payouts.